David Mahvi to Combined Modality Therapy
This is a "connection" page, showing publications David Mahvi has written about Combined Modality Therapy.
Connection Strength
0.123
-
Interferon alpha enhances expression of TAG-72 and carcinoembryonic antigen in patients with primary colorectal cancer. Cancer Immunol Immunother. 1995 May; 40(5):311-4.
Score: 0.026
-
Diagnosis and management of retroperitoneal soft-tissue sarcoma. Ann Surg. 1991 Jul; 214(1):2-10.
Score: 0.020
-
Impact of selection bias on the utilization of adjuvant therapy for pancreas adenocarcinoma. Ann Surg Oncol. 2010 Feb; 17(2):371-6.
Score: 0.018
-
Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clin Cancer Res. 2009 Aug 01; 15(15):4875-84.
Score: 0.017
-
Frozen section analysis for intraoperative margin assessment during breast-conserving surgery results in low rates of re-excision and local recurrence. Ann Surg Oncol. 2007 Oct; 14(10):2953-60.
Score: 0.015
-
Carcinoma of the pancreas. Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody. Ann Surg. 1985 Oct; 202(4):440-5.
Score: 0.013
-
Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother. 2006 Jul; 55(7):761-74.
Score: 0.013